Loading...
•
Mar 31, 2023
Mirum Pharmaceuticals Q1 2023 Earnings Report
Mirum Pharmaceuticals' Q1 2023 financial performance was reported, featuring revenue growth and advancements in LIVMARLI's commercialization and label expansion.
Key Takeaways
Mirum Pharmaceuticals reported a strong start to 2023, with total revenue of $31.6 million, including $29.1 million in net product sales for LIVMARLI. The company is progressing with the global commercial launch of LIVMARLI, label expansions, and pipeline milestones.
Total revenue reached $31.6 million, including $29.1 million from LIVMARLI net product sales.
LIVMARLI's U.S. label was expanded to include infants three months of age and older for Alagille syndrome.
Regulatory submissions for LIVMARLI in PFIC are under review in the U.S. and Europe.
Three data catalysts are expected in the second half of 2023 for LIVMARLI in biliary atresia and volixibat in primary sclerosing cholangitis and primary biliary cholangitis.
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Mirum Pharmaceuticals Revenue by Segment
Revenue by Segment
Product Sales, Net Revenue
CapyFin.com Forward Guidance
Mirum Pharmaceuticals is focused on continued commercial success for LIVMARLI, including growth in year-over-year net product sales, LIVMARLI label expansion in the U.S. and Europe, the results, conduct and progress of Mirum’s ongoing and planned studies for its product candidates, including the receipt and timing of planned data readouts, the delivery of LIVMARLI to more patients, and the regulatory approval path for its product candidates globally.
Positive Outlook
- Continued commercial success for LIVMARLI
- Growth in year over year net product sales
- LIVMARLI label expansion in the U.S. and Europe
- Results, conduct and progress of Mirum’s ongoing and planned studies for its product candidates, including the receipt and timing of planned data readouts
- Delivery of LIVMARLI to more patients, and the regulatory approval path for its product candidates globally.
Challenges Ahead
- Risks and uncertainties associated with Mirum’s business in general
- Adverse macroeconomic and geopolitical developments
- Risks described in Mirum’s filings with the Securities and Exchange Commission
- The forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect.
- Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.